Author: Avalon Health Economics LLC

Why Medical Device Companies Need to Develop Economic Evidence in the U.S.
January 14, 2016 - 3:24 pm, by
Although the U.S. lacks a centralized health technology evaluation agency, as many of the European countries maintain, in recent years there has been considerable pressure to control the rising costs of new biopharmaceuticals and medical devices.[1-5] After relatively slow growth in the 1960s, U.S. health care expenditures grew intensely in the decades between 1980 and...
Avalon CEO John Schneider presented at BMO Capital Markets’ “The Year Ahead in Healthcare: Products, Payment and Politics” on December 15, 2015
December 29, 2015 - 12:08 pm, by
Avalon CEO John Schneider, Ph.D. presented at BMO Capital Markets’ “The Year Ahead in Healthcare: Products, Payment and Politics” on December 15, 2015. The day-long symposium was focused on markets for life science products and featured presentations from industry leaders, including Boston Scientific, Medtronic, Abbott and Pfizer. Schneider delivered a lunchtime presentation on the medical...
Philipp Schuetz joins Avalon Health Economics as a Clinical Advisor
November 27, 2015 - 12:07 pm, by
Avalon Health Economics is happy to announce the addition of Philipp Schuetz, MD, MPH as our Clinical Advisor. He is a board-certified internist and endocrinologist. He has broad clinical and research interests focusing on the application of new developments in endocrinology, infectious diseases, critical illness and general medicine. He has done extensive research on hormones,...
CEO John Schneider presents at Barclays HealthCare Symposium
November 23, 2015 - 12:05 pm, by
CEO John Schneider presented at the Barclays HealthCare Symposium on 11/20 on the topic of Increasing Need to Demonstrate Economic Value in Medtech.
Reference Pricing for in vivo and in vitro Diagnostic Tests
November 16, 2015 - 3:20 pm, by
Prices in health care vary widely even within the same local market and for similar tests and treatments. This reflects differences among providers in their ability and willingness to leverage bargaining power against private insurers. For their part, consumers and patients often have been indifferent to price since they have been well covered by insurance....
Purchasing Medical Innovation: The Implications for the Medical Device Industry
October 13, 2015 - 3:17 pm, by
In an earlier blog, we reviewed the recent book by one of Avalon’s directors, James Robinson. Robinson’s book, entitled “Purchasing Medical Innovation: The Right Technology, for the Right Patient, at the Right Price” seeks to unpack the often precarious relationships among medical device makers, the purchasers of those devices, the insurers, who are often the...
Avalon’s Ivana Stojanovic will be attending the AdvaMed 2015 Med Tech Conference next week in San Diego, CA
October 1, 2015 - 12:04 pm, by
The annual AdvaMed Med Tech Conference is the leading MedTech Conference in North America, bringing more than 1,000 companies together to exchange knowledge and ideas on business development, capital formation, economic evaluation, pricing and reimbursement, educational opportunities and networking. Please let us know if you like to meet and discuss your health economics needs. To...
Physician Shortages in the U.S.: Disentangling Myth, Folklore, and Fact
September 14, 2015 - 3:14 pm, by
Much of the public media and even a substantial part of the medical literature operates on the assumption that there is a shortage of physicians in the U.S., including those specializing in primary care, intensive care, and surgery. One study, for example, estimated that the physician shortfall in the U.S. would reach 90,000 by 2025.[1]...
Controlling the Costs of Clinical Laboratory Testing in Medical Practice
August 20, 2015 - 3:08 pm, by
Today’s clinical laboratory can do much more than you think. Advances in molecular diagnostics, genetics and biomarkers have ushered in a new era of clinical laboratory capabilities. Along with these advances, however, are higher laboratory expenditures. The U.S. Medicare program spent $6.5 billion annually on laboratory in 2006. By 2010, the program was spending $8.2...
Fad Diets and Nutrition: What’s all the Fuss about Gluten?
August 13, 2015 - 3:03 pm, by
In recent years, the food industry has seen a boom in the “free from” category, including a myriad of ingredients such as high fructose corn syrup, artificial flavors, toxic pesticides, artificial hormones, antibiotics, and GMOs. One such product that has been particularly demonized recently is gluten. Celebrities from Miley Cyrus to former president Bill Clinton...
Avalon Health Economics LLC